Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | New therapies for MPNs

Jean-Jacques Kiladjian • 26 Aug 2020
Myelofibrosis Myeloproliferative Neoplasms CPI-0610 Imetelstat Momelotinib Navitoclax Pacritinib Ruxolitinib

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, explores emerging therapies for patients with myelofibrosis including pacritinib and momelotinib, JAK kinase inhibitors, as well as other agents therapies being investigated as single agents or as part of combined approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jean-Jacques Kiladjian

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
2:31
The growing role of combination approaches in MF & agents being explored
Jean-Jacques Kiladjian • 9 Oct 2023
4:35
The role of JAK2 VAF testing in risk assessment and disease monitoring in MPNs
Jean-Jacques Kiladjian • 13 Jun 2023
2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023

Related Videos

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
2:45
The addition of venetoclax to HMAs for the treatment of CMML: a retrospective PSM analysis
Douglas Tremblay • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals